Rheacell GmbH & Co. KG   Report issue

For profit Phase 2 Phase 3
Founded: Heidelberg Germany (2012)

Organization Overview

First Clinical Trial
2016
NCT02742844
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

RHEACELL GmbH & Co. KG

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute-On-Chronic Liver Failure (Phase 2)

Arterial Occlusive Diseases (Phase 2)

End Stage Liver Disease (Phase 2)

Epidermolysis Bullosa (Phase 2)

Epidermolysis Bullosa Dystrophica (Phase 2)

Hepatic Insufficiency (Phase 2)

Liver Failure (Phase 2)

Peripheral Arterial Disease (Phase 2)

Skin Ulcer (Phase 2)

Ulcer (Phase 2)

Varicose Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 7